

ASX Release

EMvision Medical Devices Ltd
ACN 620 388 230
Level 10, 12 Creek Street,
Brisbane Qld 4000
02 8667 5337
contact@emvision.com.au

PROFESSORS DONNAN, DAVIS, AND DR DOS SANTOS TO JOIN EMV'S CLINICAL ADVISORY BOARD AS EX-OFFICIO MEMBERS

EMVision Medical Devices Limited (ASX:EMV) ("EMVision" or the "Company"), a medical device company focused on the development and commercialisation of medical imaging technology, today is pleased to announce that Professors Geoffrey Donnan and Stephan Davis, eminent neurologists and recognised leaders in the field of stroke care, will join the EMVision's Clinical Advisory Board in an ex-officio capacity as Co-Chairs of the Australian Stroke Alliance. Professors Donnan and Davis will also be joined by stroke neurologist and Mobile Stroke Unit (MSU) expert Dr Angela Dos Santos.

Professor Geoff Donnan AO is a Past-President of the World Stroke Organization and was Chair of the World Congress of Neurology. Professor Donnan is co-chair of the Australian Stroke Alliance. Professor Donnan showed that brain tissue could have prolonged survival after stroke and, when salvaged, improved clinical outcomes. This provided the rationale for acute stroke therapies. Professor Donnan has been involved in a number of international initiatives, including the establishment of the World Neurology Foundation and the World Stroke Foundation.

Prof Donnan said "Working with EMVision on the clinical translation of their lightweight imaging device represents a once in a generation opportunity to revolutionise the delivery of acute stroke care to all Australians. The concept of bringing imaging to the patient will dramatically reduce times to administer life saving interventions such as thrombolysis and thrombectomy"

Professor Davis AO is the Professor of Translational Neuroscience at the University of Melbourne, Director of the Melbourne Brain Centre at the Royal Melbourne Hospital and a Past-President of the World Stroke Organization. Professor Davis is co-chair of the Australian Stroke Alliance. His research is focussed on acute therapy for both ischemic stroke and intracerebral haemorrhage, particularly the use of advanced imaging in selection of therapy. He and Professor Donnan established and lead the Melbourne Mobile Stroke Unit program, the first in Australia.

Prof Davis said "I am excited by the partnership of ASA and EMVision. The development of a light-weight, highly portable and affordable EMV brain scanner will revolutionize pre-hospital stroke care and allow deployment in standard road ambulances and aircraft, to reach rural and remote Australians."

Dr Angela Dos Santos is Australia's first Aboriginal neurologist with subspecialty training in stroke. Dr Dos Santos works at both the Royal Melbourne and the Alfred Hospital in Melbourne. Additionally, she works for ambulance Victoria as a stroke specialist, within the Victoria Stroke Telehealth Network (VST) and on the Mobile Stroke Unit (MSU). She is a senior clinical research fellow for the Australian Stroke Alliance

Dr Dos Santos said "I am proud to be on the Clinical Advisory Board for EMVision, a company who is creating mobile devices for stroke diagnosis. With so many Australians and in particular a large proportion of Aboriginal and Torres Strait Islander patients living vast distances from stroke imaging, this company holds promise in being able to reduce stroke care inequity."

EMVision CEO, Dr Ron Weinberger, commented "Geoff, Steve and Angela are incredibly strong additions to our Clinical Advisors. They bring significant international stroke care experience and connectivity, which is

important as we advance our products towards realisation and commercialisation. We have developed an excellent working relationship with Geoff, Steve and Angela via the Australian Stroke Alliance, we are privileged to have attracted them to participate in our Clinical Advisory Board and am looking forward to their ongoing guidance as we execute on our product, clinical and commercial strategy”.

Professors Donnan and Davis and Dr Dos Santos appointments are unsalaried positions.

Authorised for release by the Board of the Company.

[ENDS]

For further information, media or investor enquiries, please contact:

Andrew Keys
Investor Relations
+61 400 400 380
andrew.keys@keysthomas.com

Sling & Stone
Media and Communications
emvision@slingstone.com
02 8073 5390

Scott Kirkland
Executive Director
+61 2 8667 5337
skirkland@emvision.com.au

About EMVision Medical Devices

EMVision Medical Devices Limited is focused on the development and commercialisation of medical imaging technology. The Company is developing and seeking to commercialise a potentially cost effective, portable, medical imaging device using electromagnetic microwave imaging for diagnosis and monitoring of stroke and other medical applications. The technology is the result of over 10 years of development by researchers at the University of Queensland. The team of approximately 20 researchers is led by co-inventor Professor Amin Abbosh, who is considered a global leader in electromagnetic microwave imaging. EMVision's Chief Scientific Officer is Professor Stuart Crozier, who is a co-inventor and is globally renowned for creating technology central to most MRI machines manufactured since 1997. EMVision's CEO, Dr Ron Weinberger, is the Former Executive Director and CEO of Nanosonics' (ASX:NAN), a \$2 billion market cap healthcare company. Dr Weinberger has over 25-years' experience developing and commercialising medical devices. During his time at Nanosonics, Dr Weinberger co-developed the company's platform technology and launched their breakthrough product 'Tropon' globally, which would go on to become the gold standard for infection prevention. Dr Weinberger was instrumental in transforming Nanosonics from a research and development company to one of Australia's leading medical device commercialisation success stories.

Forward-looking Statements

This release may contain certain forward-looking statements with respect to matters including but not limited to the financial condition, results of operations and business of EMVision and certain of the plans and objectives of EMVision with respect to these items. These forward-looking statements are not historical facts but rather are based on EMVision's current expectations, estimates and projections about the industry in which EMVision operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates", "guidance" and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of EMVision, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward looking statements. EMVision cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of EMVision only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. EMVision will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.